Edwards Lifesciences Sees Q1 2024 Adj. EPS $0.62-$0.66 Vs $0.66 Est.; Revenue $1.61B Vs $1.562B Est.
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences projects its Q1 2024 adjusted EPS to be between $0.62 and $0.66, compared to the estimated $0.66. The company anticipates revenue of $1.61 billion, surpassing the estimated $1.562 billion.
February 06, 2024 | 9:18 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Edwards Lifesciences projects its Q1 2024 adjusted EPS to be between $0.62 and $0.66, slightly below or at the estimated $0.66, with revenue expectations of $1.61 billion, above the $1.562 billion estimate.
The projected EPS range indicates a potential to meet or slightly miss analyst expectations, which could lead to neutral market reactions. However, the higher revenue forecast suggests strong sales performance, potentially offsetting concerns about the EPS figures and maintaining investor confidence.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100